Effects of miR-125a-3p on Atherosclerotic Plaque, M1/M2 Macrophages, MMP-9 and VEGF
-
摘要:
目的 探讨miR-125a-3p对大耳兔动脉粥样硬化斑块形成、M1/M2巨噬细胞、基质金属蛋白酶9（MMP-9）和血管内皮生长因子（VEGF）的影响。 方法 15只成年雄性健康日本大耳兔，随机分为3组，每组5只，对照组给予普通饲料喂养，动脉粥样硬化模型组给予牛血清白蛋白注射和高胆固醇饲料喂养，miR-125a-3p抑制剂干预组给予动脉粥样硬化兔注射miR-125a-3p干扰慢病毒载体。油红O染色后图像分析法测定斑块面积，免疫组化法测定MMP-9和VEGF，免疫荧光法检测斑块组织中M1标记物CD11c和M2标记物CD206。 结果 与动脉粥样硬化组相比，miR-125a-3p抑制剂组斑块面积百分比显著降低（P < 0.0001）。与对照组相比，动脉粥样硬化组MMP-9（P < 0.001）、VEGF（P < 0.01）和CD11c（P < 0.001）水平显著升高，CD206水平显著降低（P < 0.001）；与动脉粥样硬化组相比，miR-125a-3p抑制剂干预组MMP-9（P < 0.01）、VEGF（P < 0.01）和CD11c（P < 0.001）水平有所降低，CD206水平有所升高（P < 0.001）。 结论 抑制miR-125a-3p可减轻动脉粥样硬化斑块的形成，平衡M1/M2巨噬细胞，降低斑块组织中MMP-9和VEGF的表达，miR-125a-3p可能是治疗不稳定动脉粥样硬化斑块的新靶点。 -
关键词:
- miR-125a-3p抑制剂 /
- 动脉粥样硬化 /
- M1/M2巨噬细胞 /
- 基质金属蛋白酶9 /
- 血管内皮生长因子
Abstract:Objective To investigate the effects of miR-125a-3p inhibitors on the atherosclerotic plaque formation, M1/M2 macrophages, MMP-9 and VEGF. Methods Fifteen healthy adult male Japanese big-eared rabbits were randomly divided into 3 groups with 5 rabbits in each group. Those in the control group were fed with the normal diet,, those in the atherosclerosis model group were injected with bovine serum albumin and fed with the high cholesterol diet, and those in the miR-125a-3p inhibitor intervention group were injected with miR-125a-3p to interfere with lentivirus vector. The plaque area was determined by image analysis after oil red O staining, MMP-9 and VEGF were determined by immunohistochemistry, and M1 marker CD11c and M2 marker CD206 in plaque tissues were detected by immunofluorescence. Results Compared with the atherosclerosis group, the percentage of plaque area in miR-125a-3p inhibitor group decreased significantly （P < 0.0001）. Compared with the control group, the levels of MMP-9 （P < 0.001）, VEGF （P < 0.01） and CD11c （P < 0.001） increased significantly, and the level of cd206 decreased significantly in the atherosclerosis group （P < 0.001）; Compared with the atherosclerosis group, the levels of MMP-9 （P < 0.01）, VEGF （P < 0.01） and CD11c （P < 0.001） decreased, and the level of cd206 increased in miR-125a-3p inhibitor intervention group （P < 0.001）. Conclusion Inhibition of miR-125a-3p can reduce the formation of atherosclerotic plaques, balance M1/M2 macrophages, and reduce the expression of MMP-9 and VEGF in plaque tissues.miR-125a-3p may be a new target for the treatment of unstable plaques. -
Key words:
- miR-125a-3p inhibitors /
- Atherosclerosis /
- M1/M2 macrophages /
- MMP-9 /
- VEGF
-
图 1 血管内膜油红“O”染色各组动脉粥样硬化病变区域
与对照组比较，****P < 0.0001，****P < 0.0001；与AS模型组比较，***P < 0.001。
Figure 1. Vascular intima oil red "O" staining for atherosclerotic lesions in each group
图 2 血管内膜油红“O”染色
a：对照组；b：AS模型组；c：AS模型+miR-125a-3p抑制剂干预组；miR-125a-3p抑制剂干预后动脉粥样硬化组病变区域显著减小。
Figure 2. Vascular intima is stained with oil red "O" stain
图 3 免疫组化检测各组MMP-9 表达水平
与对照组比较，***P < 0.001，*P < 0.05；与AS模型组比较，**P < 0.01。
Figure 3. The expression level of MMP-9 was detected by immunohistochemistry
图 4 MMP-9免疫组化染色（×200）
a：对照组；b：AS模型组；c：miR-125a-3p抑制剂干预组；miR-125a-3p抑制剂干预后，MMP-9表达水平显著下降。
Figure 4. MMP-9 immunohistochemical staining （×200）
图 5 免疫组化检测各组VEGF表达水平
与对照组比较，**P < 0.01，*P < 0.05；与AS模型组比较，**P < 0.01。
Figure 5. Immunohistochemistry was used to detect VEGF expression levels in each group
图 6 VEGF免疫组化染色（×200）
a：对照组；b：AS模型组；c：AS模型+miR-125a-3p抑制剂干预组；miR-125a-3p抑制剂干预后，VEGF表达水平下降。
Figure 6. VEGF immunohistochemical staining （×200）
图 7 免疫荧光检测各组M1标志物CD11c表达水平
与对照组比较，****P < 0.0001，*P < 0.05；与AS模型组比较，****P < 0.0001。
Figure 7. The expression level of M1 marker CD11c was detected by immunofluorescence
图 8 M1标志物CD11c免疫荧光染色（×200）
a：对照组；b：AS模型组；c：AS模型+miR-125a-3p抑制剂干预组；miR-125a-3p抑制剂干预后，CD11c表达水平显著下降。
Figure 8. M1 marker CD11c immunofluorescence staining （×200）
图 9 免疫荧光检测各组M2 标志物CD206表达水平
与对照组比较，****P < 0.0001，**P < 0.01；与AS模型组比较，****P < 0.0001。
Figure 9. The expression level of M2 marker CD206 was detected by immunofluorescence
-
[1] Moore K J,Sheedy F J,Fisher E A. Macrophages in atherosclerosis:A dynamic balance[J]. Nat Rev Immunol,2013,13(10):709-721. doi: 10.1038/nri3520 [2] Mills C D,Ley K. M1 and M2 macrophages:The chicken and the egg of immunity[J]. J Innate Immun,2014,6(6):716-726. doi: 10.1159/000364945 [3] Murray P J,Allen J E,Biswas S K,et al. Macrophage activation and polarization:Nomenclature and experimental guidelines[J]. Immunity,2014,41(1):14-20. doi: 10.1016/j.immuni.2014.06.008 [4] Schmitz G,Grandl M. Role of redox regulation and lipid rafts in macrophages during Ox-LDL-mediated foam cell formation[J]. Antioxid Redox Signal,2007,9(9):1499-1518. doi: 10.1089/ars.2007.1663 [5] 杨新春,张大鹏. 慢性冠状动脉综合征的概念和要点及意义[J]. 中国心血管病研究,2019,17(10):871-873. doi: 10.3969/j.issn.1672-5301.2019.10.002 [6] Stoger J L,Gijbels M J,Van Der Velden S,et al. Distribution of macrophage polarization markers in human atherosclerosis[J]. Atherosclerosis,2012,225(2):461-468. doi: 10.1016/j.atherosclerosis.2012.09.013 [7] Kuznetsova T,Prange K H M,Glass C K,et al. Transcriptional and epigenetic regulation of macrophages in atherosclerosis[J]. Nature Reviews Cardiology,2020,17(4):216-228. doi: 10.1038/s41569-019-0265-3 [8] Van der Veken B,De Meyer G R,Martinet W. Intraplaque neovascularization as a novel therapeutic target in advanced atherosclerosis[J]. Expert Opin Ther Targets,2016,20(10):1247-1257. doi: 10.1080/14728222.2016.1186650 [9] 徐声波,吴平路,余晖,等. AIS患者CTRP1、MMP-9水平与颈动脉硬化斑块稳定性及神经功能缺损程度的关系[J]. 脑与神经疾病杂志,2021,29(8):492-496. [10] Ganta V C,Choi M,Farber C R,et al. Antiangiogenic VEGF165b regulates macrophage polarization via S100A8/S100A9 in peripheral artery disease[J]. Circulation,2019,139(2):226-242. doi: 10.1161/CIRCULATIONAHA.118.034165 [11] Clemente C,Rius C,Alonso-Herranz L,et al. MT4-MMP deficiency increases patrolling monocyte recruitment to early lesions and accelerates atherosclerosis[J]. Nat Commun,2018,9(1):910. doi: 10.1038/s41467-018-03351-4 [12] 戴海龙,肖娟,潘云. 冠心病患者外周血单核细胞中miR-125a-3p的表达研究[J]. 中国心血管病研究,2020,18(3):203-205. doi: 10.3969/j.issn.1672-5301.2020.03.003 [13] Mushenkova N V,Nikiforov N G,Melnichenko A A,et al. Functional phenotypes of intraplaque macrophages and their distinct roles in atherosclerosis development and atheroinflammation[J]. Biomedicines,2022,10(2):452. doi: 10.3390/biomedicines10020452 [14] Barquera S,Pedroza-Tobias A,Medina C,et al. Global overview of the epidemiology of atherosclerotic cardiovascular disease[J]. Arch Med Res,2015,46(5):328-338. doi: 10.1016/j.arcmed.2015.06.006 [15] Guilliams M,Mildner A,Yona S. Developmental and functional heterogeneity of monocytes[J]. Immunity,2018,49(4):595-613. doi: 10.1016/j.immuni.2018.10.005 [16] Bouhlel M A,Derudas B,Rigamonti E,et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties[J]. Cell Metab,2007,6(2):137-143. doi: 10.1016/j.cmet.2007.06.010 [17] Rupaimoole R,Slack F J. MicroRNA therapeutics:towards a new era for the management of cancer and other diseases[J]. Nat Rev Drug Discov,2017,16(3):203-222. doi: 10.1038/nrd.2016.246 [18] Bartel D P. MicroRNAs:Genomics,biogenesis,mechanism,and function[J]. Cell,2004,116(2):281-297. doi: 10.1016/S0092-8674(04)00045-5 [19] Lujambio A,Lowe S W. The microcosmos of cancer[J]. Nature,2012,482(7385):347-355. doi: 10.1038/nature10888 [20] Lv L L,Feng Y,Wu M,et al. Exosomal miRNA-19b-3p of tubular epithelial cells promotes M1 macrophage activation in kidney injury[J]. Cell Death Differ,2020,27(1):210-226. doi: 10.1038/s41418-019-0349-y [21] Mao Y,Liu X,Song Y,et al. VEGF-A/VEGFR-2 and FGF-2/FGFR-1 but not PDGF-BB/PDGFR-β play important roles in promoting immature and inflammatory intraplaque angiogenesis[J]. PloS One,2018,13(8):e0201395. doi: 10.1371/journal.pone.0201395 [22] Bot P T,Pasterkamp G,Goumans M J,et al. Hyaluronic acid metabolism is increased in unstable plaques[J]. Eur J Clin Invest,2010,40(9):818-827. doi: 10.1111/j.1365-2362.2010.02326.x -
下载:
点击查看大图
计量
- 文章访问数: 3339
- HTML全文浏览量: 2313
- PDF下载量: 135
- 被引次数: 0
